bioRxiv preprint doi: https://doi.org/10.1101/2020.04.27.059600; this version posted April 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. The Alzheimer’s disease protective P522R variant of PLCG2, consistently enhances stimulus-dependent PLCγ2 activation, depleting substrate and altering cell function. Emily Maguire #1, Georgina E. Menzies#1, Thomas Phillips#1, Michael Sasner2, Harriet M. Williams2, Magdalena A. Czubala3, Neil Evans1, Emma L Cope4, Rebecca Sims5, Gareth R. Howell2, Emyr Lloyd-Evans4, Julie Williams†1,5, Nicholas D. Allen†4 and Philip R. Taylor†*1,3. 1 UK Dementia Research Institute at Cardiff, Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ, Wales, UK. 2 The Jackson Laboratory, Bar Harbor, Maine 04660, USA. 3 Systems Immunity University Research Institute, Tenovus Building, Heath Park, Cardiff CF 14 4XN, Wales, UK. 4 School of Biosciences, Cardiff University, Museum Avenue, Cardiff, CF10 3AX. 5 MRC Centre for Neuropsychiatric Genetics & Genomics, Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ, Wales, UK. #†These authors contributed equally *To whom correspondence should be addressed (lead contact): Prof Philip R. Taylor; Tel: +44(0)2920687328; Email:
[email protected]. Abstract: Recent genome-wide association studies of Alzheimer’s disease (AD) have identified variants implicating immune pathways in disease development. A rare coding variant of PLCG2, which encodes PLCγ2, shows a significant protective effect for AD (rs72824905, P522R, P=5.38x10-10, Odds Ratio = 0.68).